Human Genetics Market Research Report—Global Forecast till 2027

Human Genetics Market: Information by Application (Wellness & E-Commerce, Preventive Medicine, Diagnostic & Treatment), by Test (NIPT, Carrier Testing, Pharmacogenomic Testing, Karyotype Testing, Thrombophilia Testing, Septin 9 Biomarker Testing, NGS, Others), and by Country (US, Canada, UK, Germany, Spain, Japan)—Forecast till 2027

ID: MRFR/HC/0243-CR | February 2022 | Region: Global | 169 Pages         

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY 14

2 MARKET INTRODUCTION 15

2.1 DEFINITION 15

2.2 SCOPE OF THE STUDY 15

2.3 RESEARCH OBJECTIVE 15

2.4 MARKET STRUCTURE 15

2.5 ASSUMPTIONS & LIMITATIONS 16

3 RESEARCH METHODOLOGY 17

3.1 DATA MINING 17

3.2 SECONDARY RESEARCH 18

3.3 PRIMARY RESEARCH 19

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 20

3.5 FORECASTING TECHNIQUES 21

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22

3.6.1 BOTTOM-UP APPROACH 23

3.6.2 TOP-DOWN APPROACH 23

3.7 DATA TRIANGULATION 24

3.8 VALIDATION 24

4 MARKET DYNAMICS 25

4.1 OVERVIEW 25

4.2 DRIVERS 26

4.2.1 GROWING ADOPTION OF GENETIC TESTING 26

4.2.2 INCREASING INCIDENCES OF GENETIC DISEASES AND CANCER 26

4.3 RESTRAINTS 27

4.3.1 HIGH COST OF GENETIC TESTING 27

4.3.2 SHORTAGE OF SKILLED AND EXPERIENCED GENETIC COUNSELORS 27

4.4 OPPORTUNITY 28

4.4.1 GROWING USE OF GENETIC DATA ACROSS HEALTHCARE AND TECHNOLOGICAL ADVANCEMENTS IN GENETIC TESTING 28

5 MARKET FACTOR ANALYSIS 29

5.1 VALUE CHAIN ANALYSIS 29

5.1.1 R&D 30

5.1.2 MANUFACTURING 30

5.1.3 DISTRIBUTION & SALES 30

5.1.4 POST-SALES MONITORING 30

5.2 PORTER'S FIVE FORCES MODEL 31

5.2.1 THREAT OF NEW ENTRANTS 31

5.2.2 BARGAINING POWER OF SUPPLIERS 32

5.2.3 THREAT OF SUBSTITUTES 32

5.2.4 BARGAINING POWER OF BUYERS 32

5.2.5 INTENSITY OF RIVALRY 32

5.3 IMPACT OF COVID-19 ON THE GLOBAL HUMAN GENETICS MARKET 32

5.3.1 IMPACT ON SUPPLY CHAIN 32

5.3.2 IMPACT ON PATIENTS SUFFERING FROM GENETIC DISEASES 33

5.3.3 IMPACT ON KEY PLAYERS 33

6 GLOBAL HUMAN GENETICS MARKET, BY APPLICATION 34

6.1 OVERVIEW 34

6.2 WELLNESS & E-COMMERCE 35

6.3 PREVENTIVE MEDICINE 35

6.4 DIAGNOSTIC & TREATMENT 36

7 GLOBAL HUMAN GENETICS MARKET, BY TEST 42

7.1 OVERVIEW 42

7.2 NIPT 43

7.3 CARRIER TESTING 44

7.4 PHARMACOGENOMIC TESTING 45

7.5 KARYOTYPE TESTING 46

7.6 THROMBOPHILIA TESTING 47

7.7 SEPTIN 9 BIOMARKER TESTING 48

7.8 NGS 49

7.9 OTHERS 51

8 GLOBAL HUMAN GENETICS MARKET, BY COUNTRY 52

8.1 OVERVIEW 52

8.1.1 US 53

8.1.2 CANADA 55

8.1.3 UK 57

8.1.4 GERMANY 59

8.1.5 SPAIN 61

8.1.6 JAPAN 63

8.1.7 OTHERS 65

9 COMPETITIVE LANDSCAPE 67

9.1 OVERVIEW 67

9.2 COMPETITIVE BENCHMARKING 68

9.3 MAJOR GROWTH STRATEGY IN THE HUMAN GENETICS MARKET 69

9.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE HUMAN GENETICS MARKET 70

9.5 KEY DEVELOPMENT ANALYSIS 71

9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 71

9.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL 71

9.6.2 MERGER &ACQUISITION 71

9.6.3 EXPANSION 72

9.7 FINANCIAL MATRIX 72

9.7.1 SALES (USD MILLION), 2020 72

10 COMPANY PROFILES 73

10.1 MYRIAD GENETICS, INC. 73

10.1.1 COMPANY OVERVIEW 73

10.1.2 FINANCIAL OVERVIEW 74

10.1.3 PRODUCT/SERVICE OFFERED 75

10.1.4 KEY DEVELOPMENTS 75

10.1.5 SWOT ANALYSIS 76

10.1.6 KEY STRATEGIES 76

10.2 SYNLAB GROUP 77

10.2.1 COMPANY OVERVIEW 77

10.2.2 FINANCIAL OVERVIEW 77

10.2.3 PRODUCT/SERVICE OFFERED 78

10.2.4 KEY DEVELOPMENTS 78

10.2.5 SWOT ANALYSIS 79

10.2.6 KEY STRATEGIES 79

10.3 EUROFINS MEGALAB S.A. 80

10.3.1 COMPANY OVERVIEWS 80

10.3.2 FINANCIAL OVERVIEW 80

10.3.3 PRODUCT/SERVICE OFFERED 81

10.3.4 KEY DEVELOPMENTS 81

10.3.5 SWOT ANALYSIS 81

10.3.6 KEY STRATEGIES 82

10.4 BIOMARKER TECHNOLOGIES. 83

10.4.1 COMPANY OVERVIEW 83

10.4.2 FINANCIAL OVERVIEW 83

10.4.3 PRODUCT/SERVICE OFFERED 83

10.4.4 KEY DEVELOPMENTS 83

10.4.5 SWOT ANALYSIS 84

10.4.6 KEY STRATEGIES 84

10.5 ECHEVARNE LABORATORY 85

10.5.1 COMPANY OVERVIEW 85

10.5.2 FINANCIAL OVERVIEW 85

10.5.3 PRODUCT/SERVICE OFFERED 85

10.5.4 KEY DEVELOPMENTS 85

10.5.5 SWOT ANALYSIS 86

10.5.6 KEY STRATEGIES 86

10.6 ELABSCIENCE BIOTECHNOLOGY INC. 87

10.6.1 COMPANY OVERVIEW 87

10.6.2 FINANCIAL OVERVIEW 87

10.6.3 PRODUCT/SERVICE OFFERED 87

10.6.4 KEY DEVELOPMENTS 87

10.6.5 SWOT ANALYSIS 88

10.6.6 KEY STRATEGIES 88

10.7 NIMGENETICS 89

10.7.1 COMPANY OVERVIEW 89

10.7.2 FINANCIAL OVERVIEW 89

10.7.3 PRODUCT/SERVICE OFFERED 89

10.7.4 KEY DEVELOPMENTS 90

10.7.5 SWOT ANALYSIS 90

10.7.6 KEY STRATEGIES 90

10.8 SISTEMAS GENÓMICOS 91

10.8.1 COMPANY OVERVIEW 91

10.8.2 FINANCIAL OVERVIEW 91

10.8.3 PRODUCTS/SERVICES OFFERED 91

10.8.4 KEY DEVELOPMENTS 91

10.8.5 SWOT ANALYSIS 92

10.8.6 KEY STRATEGIES 92

10.9 FULLGENOMICS 93

10.9.1 COMPANY OVERVIEW 93

10.9.2 FINANCIAL OVERVIEW 93

10.9.3 PRODUCTS/SERVICES OFFERED 93

10.9.4 KEY DEVELOPMENTS 93

10.9.5 SWOT ANALYSIS 94

10.9.6 KEY STRATEGIES 94

10.10 GENINCODE 95

10.10.1 COMPANY OVERVIEW 95

10.10.2 FINANCIAL OVERVIEW 95

10.10.3 PRODUCTS/SERVICES OFFERED 95

10.10.4 KEY DEVELOPMENTS 95

10.10.5 SWOT ANALYSIS 96

10.10.6 KEY STRATEGIES 96

10.11 ATRYS HEALTH 97

10.11.1 COMPANY OVERVIEW 97

10.11.2 FINANCIAL OVERVIEW 97

10.11.3 PRODUCTS/SERVICES OFFERED 97

10.11.4 KEY DEVELOPMENTS 97

10.11.5 SWOT ANALYSIS 98

10.11.6 KEY STRATEGIES 98

10.12 GENYCA 99

10.12.1 COMPANY OVERVIEW 99

10.12.2 FINANCIAL OVERVIEW 99

10.12.3 PRODUCTS/SERVICES OFFERED 99

10.12.4 KEY DEVELOPMENTS 99

10.12.5 SWOT ANALYSIS 100

10.12.6 KEY STRATEGIES 100

10.13 IGENOMIX 101

10.13.1 COMPANY OVERVIEW 101

10.13.2 FINANCIAL OVERVIEW 101

10.13.3 PRODUCTS/SERVICES OFFERED 101

10.13.4 KEY DEVELOPMENTS 101

10.13.5 SWOT ANALYSIS 102

10.13.6 KEY STRATEGIES 102

10.14 GENOLÓGICA 103

10.14.1 COMPANY OVERVIEW 103

10.14.2 FINANCIAL OVERVIEW 103

10.14.3 PRODUCTS/SERVICES OFFERED 103

10.14.4 KEY DEVELOPMENTS 103

10.14.5 SWOT ANALYSIS 104

10.14.6 KEY STRATEGIES 104

10.15 BODE CELLMARK FORENSICS, INC. 105

10.15.1 COMPANY OVERVIEW 105

10.15.2 FINANCIAL OVERVIEW 105

10.15.3 PRODUCTS/SERVICES OFFERED 105

10.15.4 KEY DEVELOPMENTS 105

10.15.5 SWOT ANALYSIS 106

10.15.6 KEY STRATEGIES 106

11 APPENDIX 107

11.1 REFERENCES 107

11.2 RELATED REPORTS 107


LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 16

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 19

TABLE 3 GLOBAL HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 34

TABLE 4 GLOBAL HUMAN GENETICS MARKET FOR WELLNESS & E-COMMERCE, BY COUNTRY, 2018–2027 (USD MILLION) 35

TABLE 5 GLOBAL HUMAN GENETICS MARKET FOR PREVENTIVE MEDICINE, BY COUNTRY, 2018–2027 (USD MILLION) 36

TABLE 6 GLOBAL HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY COUNTRY, 2018–2027 (USD MILLION) 37

TABLE 7 GLOBAL HUMAN GENETICS MARKET FOR APPLICATION, BY DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 37

TABLE 8 GLOBAL HUMAN GENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2018–2027 (USD MILLION) 38

TABLE 9 GLOBAL HUMAN GENETICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2018–2027 (USD MILLION) 38

TABLE 10 GLOBAL HUMAN GENETICS MARKET FOR NEUROLOGY, BY COUNTRY, 2018–2027 (USD MILLION) 39

TABLE 11 GLOBAL HUMAN GENETICS MARKET FOR ASSISTED REPRODUCTION, BY COUNTRY, 2018–2027 (USD MILLION) 39

TABLE 12 GLOBAL HUMAN GENETICS MARKET FOR GYNECOLOGY, BY COUNTRY, 2018–2027 (USD MILLION) 40

TABLE 13 GLOBAL HUMAN GENETICS MARKET FOR OTHERS, BY COUNTRY, 2018–2027 (USD MILLION) 40

TABLE 14 GLOBAL HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 40

TABLE 15 GLOBAL HUMAN GENETICS MARKET FOR NEUROPEDIATRIC, BY COUNTRY, 2018–2027 (USD MILLION) 41

TABLE 16 GLOBAL HUMAN GENETICS MARKET FOR OTHERS, BY COUNTRY, 2018–2027 (USD MILLION) 41

TABLE 17 GLOBAL HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 43

TABLE 18 GLOBAL HUMAN GENETICS MARKET FOR NIPT, BY COUNTRY, 2018–2027 (USD MILLION) 44

TABLE 19 GLOBAL HUMAN GENETICS MARKET FOR CARRIER TESTING, BY COUNTRY, 2018–2027 (USD MILLION) 45

TABLE 20 GLOBAL HUMAN GENETICS MARKET FOR PHARMACOGENOMIC TESTING, BY COUNTRY, 2018–2027 (USD MILLION) 46

TABLE 21 GLOBAL HUMAN GENETICS MARKET FOR KARYOTYPE TESTING, BY COUNTRY, 2018–2027 (USD MILLION) 47

TABLE 22 GLOBAL HUMAN GENETICS MARKET FOR THROMBOPHILIA TESTING, BY COUNTRY, 2018–2027 (USD MILLION) 48

TABLE 23 GLOBAL HUMAN GENETICS MARKET FOR SEPTIN 9 BIOMARKER TESTING, BY COUNTRY, 2018–2027 (USD MILLION) 48

TABLE 24 GLOBAL HUMAN GENETICS MARKET FOR NGS, BY COUNTRY, 2018–2027 (USD MILLION) 49

TABLE 25 GLOBAL HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 49

TABLE 26 GLOBAL HUMAN GENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2018–2027 (USD MILLION) 49

TABLE 27 GLOBAL HUMAN GENETICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2018–2027 (USD MILLION) 50

TABLE 28 GLOBAL HUMAN GENETICS MARKET FOR OTHERS, BY COUNTRY, 2018–2027 (USD MILLION) 51

TABLE 29 GLOBAL HUMAN GENETICS MARKET FOR OTHERS, BY COUNTRY, 2018–2027 (USD MILLION) 51

TABLE 30 GLOBAL HUMAN GENETICS MARKET, BY COUNTRY, 2018–2027 (USD MILLION) 52

TABLE 31 US: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 53

TABLE 32 US: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 53

TABLE 33 US: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 54

TABLE 34 US: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 54

TABLE 35 US: HUMAN GENETICS MARKET FOR BY NGS, BY TYPE, 2018–2027 (USD MILLION) 54

TABLE 36 CANADA: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 55

TABLE 37 CANADA: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 55

TABLE 38 CANADA: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 56

TABLE 39 CANADA: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 56

TABLE 40 CANADA: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 56

TABLE 41 UK: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 57

TABLE 42 UK: HUMAN GENETICS MARKET FOR BY DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 57

TABLE 43 UK: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 58

TABLE 44 UK: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 58

TABLE 45 UK: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 58

TABLE 46 GERMANY: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 59

TABLE 47 GERMANY: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 59

TABLE 48 GERMANY: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 60

TABLE 49 GERMANY: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 60

TABLE 50 GERMANY: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 60

TABLE 51 SPAIN: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 61

TABLE 52 SPAIN: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, FOR TYPE, 2018–2027 (USD MILLION) 61

TABLE 53 SPAIN: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 62

TABLE 54 SPAIN: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 62

TABLE 55 SPAIN: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 62

TABLE 56 JAPAN: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 63

TABLE 57 JAPAN: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 63

TABLE 58 JAPAN: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 64

TABLE 59 JAPAN: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 64

TABLE 60 JAPAN: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 64

TABLE 61 OTHERS: HUMAN GENETICS MARKET, BY APPLICATION, 2018–2027 (USD MILLION) 65

TABLE 62 OTHERS: HUMAN GENETICS MARKET FOR DIAGNOSTIC & TREATMENT, BY TYPE, 2018–2027 (USD MILLION) 65

TABLE 63 OTHERS: HUMAN GENETICS MARKET FOR NEUROLOGY, BY TYPE, 2018–2027 (USD MILLION) 66

TABLE 64 OTHERS: HUMAN GENETICS MARKET, BY TEST, 2018–2027 (USD MILLION) 66

TABLE 65 OTHERS: HUMAN GENETICS MARKET FOR NGS, BY TYPE, 2018–2027 (USD MILLION) 66

TABLE 66 MAJOR PLAYERS IN THE HUMAN GENETICS MARKET 67

TABLE 67 MOST ACTIVE PLAYER IN THE HUMAN GENETICS MARKET 70

TABLE 68 PRODUCT LAUNCH/PRODUCT APPROVAL 71

TABLE 69 MERGER & ACQUISITION 71

TABLE 70 EXPANSION 72

TABLE 71 MYRIAD GENETICS INC.: PRODUCT/SERVICE OFFERED 75

TABLE 72 MYRIAD GENETICS INC.: KEY DEVELOPMENTS 75

TABLE 73 SYNLAB GROUP: PRODUCT/SERVICE OFFERED 78

TABLE 74 SYNLAB GROUP: KEY DEVELOPMENTS 78

TABLE 75 EUROFINS MEGALAB S.A: PRODUCT/SERVICE OFFERED 81

TABLE 76 BIOMARKER TECHNOLOGIES: PRODUCT/SERVICE OFFERED 83

TABLE 77 ECHEVARNE LABORATORY: PRODUCT /SERVICE OFFERED 85

TABLE 78 ELABSCIENCE BIOTECHNOLOGY INC.: PRODUCT/SERVICE OFFERED 87

TABLE 79 NIMGENETICS: PRODUCT/SERVICE OFFERED 89

TABLE 80 SISTEMAS GENÓMICOS: PRODUCTS OFFERED 91

TABLE 81 FULLGENOMICS: PRODUCTS/SERVICES OFFERED 93

TABLE 82 GENINCODE: PRODUCTS/SERVICES OFFERED 95

TABLE 83 GENINCODE: KEY DEVELOPMENTS 95

TABLE 84 ATRYS HEALTH: PRODUCTS/SERVICES OFFERED 97

TABLE 85 GENYCA: PRODUCTS/SERVICES OFFERED 99

TABLE 86 IGENOMIX: PRODUCTS/SERVICES OFFERED 101

TABLE 87 IGENOMIX: KEY DEVELOPMENTS 101

TABLE 88 GENOLOGICA: PRODUCTS/SERVICES OFFERED 103

TABLE 89 BODE CELLMARK FORENSICS, INC.: PRODUCTS/SERVICES OFFERED 105


LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS 14

FIGURE 2 GLOBAL HUMAN GENETICS MARKET 15

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 22

FIGURE 4 MARKET DYNAMICS: GLOBAL HUMAN GENETICS MARKET 25

FIGURE 5 DRIVER IMPACT ANALYSIS 27

FIGURE 6 RESTRAINT IMPACT ANALYSIS 28

FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL HUMAN GENETICS MARKET 29

FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL HUMAN GENETICS MARKET 31

FIGURE 9 GLOBAL HUMAN GENETICS MARKET, BY APPLICATION, 2020 AND 2027 (USD MILLION) 34

FIGURE 10 GLOBAL HUMAN GENETICS MARKET, BY TEST, 2020 AND 2027 (USD MILLION) 42

FIGURE 11 GLOBAL HUMAN GENETICS MARKET SHARE (%), BY COUNTRY, 2020 52

FIGURE 12 BENCHMARKING OF MAJOR COMPETITORS 68

FIGURE 13 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE HUMAN GENETICS MARKET 69

FIGURE 14 HUMAN GENETICS MARKET: COMPETITIVE LANDSCAPE 71

FIGURE 15 SALES (USD MILLION), 2020 72

FIGURE 16 MYRIAD GENETICS INC.: FINANCIAL OVERVIEW SNAPSHOT 74

FIGURE 17 MYRIAD GENETICS INC.: SWOT ANALYSIS 76

FIGURE 18 SYNLAB GROUP: FINANCIAL OVERVIEW SNAPSHOT 77

FIGURE 19 SYNLAB GROUP: SWOT ANALYSIS 79

FIGURE 20 EUROFINS MEGALAB S.A.: FINANCIAL OVERVIEW SNAPSHOT 80

FIGURE 21 EUROFINS MEGALAB S.A: SWOT ANALYSIS 81

FIGURE 22 BIOMARKER TECHNOLOGIES: SWOT ANALYSIS 84

FIGURE 23 ECHEVARNE LABORATORY: SWOT ANALYSIS 86

FIGURE 24 ELABSCIENCE BIOTECHNOLOGY INC.: SWOT ANALYSIS 88

FIGURE 25 NIMGENETICS: SWOT ANALYSIS 90

FIGURE 26 SISTEMAS GENÓMICOS: SWOT ANALYSIS 92

FIGURE 27 FULLGENOMICS: SWOT ANALYSIS 94

FIGURE 28 GENINCODE: SWOT ANALYSIS 96

FIGURE 29 ATRYS HEALTH: SWOT ANALYSIS 98

FIGURE 30 GENYCA: SWOT ANALYSIS 100

FIGURE 31 IGENOMIX: SWOT ANALYSIS 102

FIGURE 32 GENOLOGICA: SWOT ANALYSIS 104

FIGURE 33 BODE CELLMARK FORENSICS, INC.: SWOT ANALYSIS 106

Human Genetics Market

Human genetics market is expected to cross USD 1,12,536.54 million by 2027 at a CAGR of 17.76%

Segmentation

By Application Wellness & E Commerce Preventive Medicine Diagnostic & Treatment
By Test Nipt Carrier Testing Pharmacogenomic Testing Karyotype Testing Thrombophilia Testing Septin 9 Biomarker Testing Ngs Others

Key Players

  • Myriad Genetics (US)
  • Synlab Group (Germany)
  • Eurofins Megalab S.A (Spain)
  • Biomarker Technology (US)
  • Echevarne Laboratory (Spain)
  • Elabscience Biotechnology Inc (US)
  • NIMGenetics (Spain)
  • Sistemas Genómicos (Spain)
  • FullGenomics (Spain)
  • GENinCode (UK)
  • Atrys Health (Spain)

Drivers

  • Increasing number of patients with genetic diseases and increasing healthcare expenditure by major economies across the globe
Speak to Analyst Request a Free Sample

Human Genetics Market Forecast


The global human genetics market is expected to cross USD 1,12,536.54 million by 2027 at a CAGR of 17.76%.


Market Overview:


Human genetics is the study of the transmittance of genes through generations.  Modification in the genome may result in mutation, a small part of which may lead to the disease phenotype. Genetic diseases can be monogenic, multifactorial, and chromosomal are passed down from the parents to the progeny by different inheritance patterns, such as X-linked recessive, autosomal recessive, and autosomal dominant. Growing prevalence of epilepsy amongst the geriatric population act as major driver in the global human genetics market during 2021–2027. However, high cost of genetic testing hinders the growth of the global human genetics market during the forecast period. The growing use of genetic data across healthcare and technological advancement in genetic testing is expected to create an opportunity in the global human genetics market.


COVID-19 Analysis:


The pandemic has affected the business landscape for many organizations around the world. As a result of the pandemic, a number of countries-imposed import and export restrictions. This has also affected the healthcare industry as many countries are dependent on other countries for raw material supply, component supply, system supply, and technology, which particularly hit Spain as it imports the majority of its products. Raw materials required for genetic testing, such as reagents, consumables, and equipment, saw a shortage that hampered the market. Furthermore, in the initial phase of the pandemic, the supply chain of Personal Protective Equipment (PPE) has been completely disrupted kits which also impacted the market as patients and staff need to work in close proximity on a regular basis. However, as the restrictions are lifted as COVID-19 cases decreases, vaccines are made available in different parts of the world, and the trade restrictions are lifted, the supply chain should return to normalcy soon. 


Genetic diseases patients mostly rely on a genetic consultant or a genetic specialist for diagnosis & treatment of genetic disorders such as chromosomal abnormalities, Down syndrome, cystic fibrosis, muscular dystrophy, Huntington's disease, familial cancer & cancer-prone diseases, and others. Due to the COVID-19 restrictions and risk of getting infected by the virus, there was an extreme case of stress on these patients and health workers. With a disruption in clinical genetic counseling across Spain, Face-to-Face (FTF) visits in both primary and secondary care were canceled or limited.


The main target for the companies in this COVID-19 situation would be to provide services to the client base at a minimal price or at least with the same pricing for genetic testing services. This may come as a challenge for the market players as their costs are supposedly rising, especially due to the new talent acquisition they are doing to cope with the rise in demand. In addition, sanitization and hygiene practices in the office and extra benefits are given to the employees keeping in mind the pandemic situation, increasing the cost. Moreover, due to stricter lockdown measures, many genetic testing companies in Spain are offering home sample collection facilities, which further increases the overall cost of the test.


Market Dynamics:


Market Drivers


  • Growing adoption of genetic testing


A genetic test is a type of medical investigation that evaluates for mutations in genes, chromosomes, or proteins. A sample of blood, hair, skin, amniotic fluid, or other tissue is used to undertake genetic tests. Depending on the suspected disease, the sample is submitted to a laboratory where technicians examine for specific alterations in chromosomes, DNA, or proteins. The laboratory sends test results to a doctor or the patient directly if required. In addition, different types of tests are performed to diagnose genetic disorders such as predictive & pre-symptomatic testing, carrier testing, prenatal & neonatal testing, diagnostic testing, pharmacogenomic testing, and other genetic tests can help to determine whether a person has a genetic condition or is at risk of developing one in the future. It also contributes to a variety of aspects, like detecting a genetic condition, initiating treatment, implementing prevention measures, and making life decisions like career choice & family planning.



  • Increasing incidences of genetic diseases and cancer


Market Restraints



  • High cost of genetic testing


The high cost of genetic testing is adversely affecting the market growth in Spain. The genetic test normally costs between USD 100 and USD 2,000, depending on the complexity involved in the test. To get the desired result, more than one test is required, leading to a rise in the cost. Despite several advancements in genetic testing, there has not been a significant decrease in the cost. Furthermore, spending on genetic tests is often not recovered or only partly compensated by most insurance plans, resulting in growing unwillingness among consumers to opt for these tests.


Some genetic testing companies charge separately for sample collection and analysis, which further increases the overall cost of the test. Therefore, the high cost of genetic testing coupled with a lack of insurance cover is likely to hinder the market growth over the forecast duration.


Market Opportunities


  • Growing use of genetic data across healthcare and technological advancement in genetic testing


Genetic testing involves several kinds of tests, such as Noninvasive Prenatal Testing (NIPT), carrier testing, pharmacogenomic testing, karyotype testing, thrombophilia testing, predictive testing, ancestry & relationship testing, and others. These tests are gaining traction across Spain. To make an informed decision, data collected from these tests are being used to study the history of diseases. In addition, personalized data collected through genetic testing helps consumers in becoming more proactive about their health, which provides a lucrative opportunity for the growth of the market.


Global Human Genetics Market Share, by Application, 2020 (%)
Global Human Genetics Market Share by Application 2020
Source: MRFR Analysis


Value Chain Analysis/Technology Analysis/Regulatory Implications


 The global human genetics market is growing at a significant rate and is expected to continue growing at the same rate in the near future. This is due to the growing contribution of existing players to make the product available to the public, the growing adoption of genetic testing, and the increasing incidences of genetic diseases and cancer. The value chain analysis for the human genetics market comprises four major components: research and product development, manufacturing, distribution & sales, and post-sales monitoring.


In the research and product development stage, new techniques and research are undertaken to make the products better and unique. R&D is a brainstorming process and requires high knowledge and skills. The product development process starts with conceptualization, followed by the design of the product, then the development, and finally, the testing. The R&D team works on improving techniques that focus on customer needs.


In this stage, the product strategies are ready, and the manufacturing process of the product starts. The manufacturing process begins with the assembling of raw materials. Sourcing of raw material is the initial phase in manufacturing genetic tests or genetic testing consumables & products. This is a crucial part of the manufacturing of the products. Raw materials, including cryopreservation solutions, culture media, and other chemicals, are extensively utilized in manufacturing genetic tests or genetic testing consumables & products.


Distribution is an integral part of any industry. In the global human genetics market, the distribution includes intermediaries, direct selling, online channels, and others. For this, the company's marketing and sales strategies play a crucial role in understanding the characteristics of the industry in which one is competing. Many players sponsor seminars, knowledge sessions, and other activities, including checking for potential interactions and providing advice, each expected to guarantee the patient gets the awareness, full advantage, and value from the products.


Post-sales monitoring plays a vital role in this market. As the global human genetics market is competitive and patient-centric, post-sales monitoring is a necessary element of the process. Thus, post-sales monitoring and reviews are crucial to understanding the changing market and meet full customer satisfaction. Post-marketing monitoring involves monitoring the efficiency of genetic testing. Some companies perform different surveys to generate post-sale reviews to identify the positive and negative points of genetic testing.


Segment Overview


The global human genetics market has been divided based on application, test.


By Application



  • Wellness & E-Commerce


Health and wellness have gained a lot of recognition in consumer conscience in the era of customization, where consumers can personalize every aspect of their lives. Increasing demand for integrating personalization into medical, nutrition, & wellness services owing to the growing consumer shift from the traditional one-size-fits-all approach towards health, nutrition, & wellness, is aiding segment growth. In addition, increasing utilization of genetic testing for creating diet & fitness plans for consumers based on their genetic profiles and rising adoption of online channels for purchasing test reports owing to the convenience offered is further bolstering segment adoption.



  • Preventive Medicine


Healthcare is witnessing a significant transition from treatment to prevention owing to the rising awareness regarding genetic testing among consumers. Genetic screening is the future of preventative medicine in the primary care setting and is an important medical tool for assessing various inheritable diseases, conditions, and cancers. Increasing adoption of genetic testing is enabling healthcare providers to prevent the disease by diagnosing the patient before the onset of any symptom or by lessening the severity of symptoms, thereby promoting quality of life.



  • Diagnostic & Treatment


Genetic testing enables doctors to determine underlying genetic conditions, which, in turn, supports in providing better diagnostics and treatment. In addition, they are also utilized in confirming a diagnosis in a symptomatic individual or used to monitor the prognosis of a disease or response to treatment. For instance, predictive or predispositional genetic testing supports in identifying individuals that are at risk of getting a disease before the onset of symptoms. Technological advancements in assessing genetic conditions coupled with increasing consumer awareness and understanding of human genetics have enabled segment adoption.


By Test


On the basis of the test, the market is divided into NIPT, carrier testing, pharmacogenomic testing, karyotype testing, thrombophilia testing, septin 9 biomarker testing, NGS, others.



  • NIPT


Non-Invasive Prenatal Testing (NIPT) supports screening maternal plasma for fetal aneuploidies by using cell-free 'fetal' DNA (cffDNA) produced from placental apoptosis. In addition, it is also offered as an alternative to traditional invasive testing procedures (amniocentesis/chorionic villus sampling) for avoiding procedure-related miscarriage risks. High accuracy coupled with low false-positive rates offered by NIPT for detecting Trisomy 18, 13, and 21 have further revolutionized the prenatal screening landscape.



  • Carrier Testing


Carrier screening is a genetic test that determines whether a healthy individual is a carrier of a recessive genetic condition such as tay-sachs disease, cystic fibrosis, sickle cell disease, hemophilia, alpha-thalassemia, and fragile X syndrome. As per the data published by Cystic Fibrosis Foundation, more than 30,000 in the US and 70,000 worldwide children and adults are affected by CF. In addition, carrier testing also offers life-lasting information regarding an individual's reproductive risk and chances of having a child with a genetic disease.



  • Pharmacogenomic Testing


Pharmacogenetics, also known as pharmacogenomics, is the study of how genes influence the body's response to certain medicines and aims to improve medication safety and dosing by incorporating patients' genetic information into treatment decisions. Benefits offered by this testing, such as improving safety by lowering the occurrence of adverse drug reactions and improving the chances of therapeutic efficacy is bolstering the segment growth. The rise in the number of companies offering this testing is aiding segment growth.



  • Karyotype Testing


Karyotyping is a test that examines the chromosomes in a sample of cells to identify genetic abnormalities causing a disorder or disease. These tests are being performed for analyzing health disorders such as down syndrome, Edwards syndrome, Patau syndrome, Turner syndrome, and Klinefelter syndrome. Increasing utilization of these tests for checking an unborn baby for genetic disorders, diagnosing a genetic disease in a baby or young child, checking a stillborn baby to see if a chromosomal defect was the cause of death, identifying if a chromosomal defect is preventing a woman from getting pregnant or is causing miscarriages, and diagnosing or tailoring a treatment plan for certain types of cancer and blood disorders is bolstering segment growth.



  • Thrombophilia Testing


Thrombophilia is a multifactorial medical term that refers to a condition in which the blood has an elevated tendency to clot and is regarded hypercoagulable. This disorder, which might increase the risk of pathological thrombosis, can be hereditary, acquired, or a combination of both. Increasing adoption of Thrombophilia testing to gather evidence of inherited deficiencies of naturally occurring anticoagulants; Protein C, antithrombin & Protein S, and rise in government approvals regarding these testing procedures boost segment growth.



  • SEPT9 Biomarker Testing


Growing consumer awareness regarding genetic testing, lifestyle changes, increasing prevalence of cancer & other genetic disorders, and rising adoption of these tests for early disease detection & diagnosis is driving the segment growth. A sensitive blood-based CRC screening test based on the SEPT9 biomarker detects the majority of CRCs of all stages and colorectal sites. It can be administered to patients at average risk for CRC who are reluctant or unable to undergo colonoscopy.



  • NGS


Next-Generation Sequencing (NGS) is a type of DNA sequencing technology that utilizes parallel sequencing of multiple small DNA fragments for determining sequence. This "high-throughput" technology has supported a significant rise in the speed (and a decrease in the cost) for sequencing an individual's genome. With the improvement and development of novel sequencing technology, NGS has been applied increasingly in cancer genomics research and clinical oncology to advance personalized cancer treatment.



  • Other


Other segments include newborn screening, diagnostic testing, preimplantation testing, forensic testing, and predictive & presymptomatic testing. Newborn screening is performed just after birth for identifying genetic disorders in babies that can be treated early in life. As per the data published by March of Dimes in July 2020, around 4 million babies are screened every year in the US Preimplantation Genetic Diagnosis (PGD), also known as preimplantation testing, is a specialized method that can lower the risk of conceiving a child with a specific genetic or chromosomal problem.


Global Human Genetics Market Share, by Region, 2020 (%)
Global Human genetics Market Share By Region 2020
Source: MRFR Analysis


Regional Analysis


The global human genetics market, based on region, has been divided into US, Canada, UK, Germany, Spain, Japan, Others.


US:


The human genetics market in the US benefits from a high healthcare expenditure, increasing demand for genetic testing by the population, and high public awareness regarding early detection of diseases and preventive care. Moreover, the availability of reimbursements in the US for genetic tests further improves market growth in the country. For instance, in October 2019, United HealthCare Services, Inc. (US), the largest health insurance company in the US, started providing insurance coverage for multi-panel genetic testing.


UK:


Clinically directed genetic testing has been available for several decades in the NHS for predictive testing for family members and molecular genetic investigation of a clinical presentation. Genomic health data in the UK is generated in three major areas, including large-scale research programs, the healthcare system, and purchasing of direct-to-consumer genetic testing. Moreover, the rise in the number of initiatives undertaken by the public as well as private organizations is further aiding the market growth.


Germany:


The rising prevalence of genetic disorders, cancer, increasing awareness and acceptance regarding personalized medicines, and growing focus on R&D activities contribute to the country's growth. As per the data published by Global Cancer Observatory in March 2021, cancer accounted for 628,516 new cases and 252,065 deaths in Germany in 2020. In addition, the government is implementing a number of favorable and collaborative policies to incorporate genetic testing into the healthcare system and provide insurance reimbursements to citizens, which, in turn, is driving the market growth.


Japan:


DNA testing at home in Japan is gaining traction among the elderly population seeking answers regarding their health and disease risks. For instance, test kits offered by Genesis Healthcare and GeneLife are suitable for users aged 18 or older, especially the elderly population in the country who appreciates the convenience offered by these test kits in keeping tabs on their health. In addition, an increase in the number of strategic initiatives by market players is further driving the market growth in the country. For instance, in April 2021, Softbank led an investment of USD 1.2 billion in Invitae in the form of convertible debts.


Competitive Landscape


The key players operating in the global human genetics include Myriad Genetics (US), Synlab Group (Germany), Eurofins Megalab S.A (Spain), Biomarker Technology (US), Echevarne Laboratory (Spain), Elabscience Biotechnology Inc (US), NIMGenetics (Spain), Sistemas Genómicos (Spain), FullGenomics (Spain), GENinCode (UK), Atrys Health (Spain), Genyca (Spain), Igenomix (India), Genologica (Spain), Bode Technology Group Inc (US). The growing use of genetic data across healthcare and technological advancements in genetic testing will provide growth opportunities for the market in the future. However, the high cost of genetic testing and shortage of skilled and experienced genetic counselors might hamper the market's growth in the forecast period.


List of Key Companies Covered in this report:



  • Myriad Genetics (US)

  • Synlab Group (Germany)

  • Eurofins Megalab S.A (Spain)

  • Biomarker Technology (US)

  • Echevarne Laboratory (Spain)

  • Elabscience Biotechnology Inc (US)

  • NIMGenetics (Spain)

  • Sistemas Genómicos (Spain)

  • FullGenomics (Spain)

  • GENinCode (UK)

  • Atrys Health (Spain)

  • Genyca (Spain)

  • Igenomix (India)

  • Genologica (Spain)

  • Bode Technology Group Inc (US). 


Recent Developments



  • In October 2021, Igenomix launched a non-invasive prenatal genetic screening test-NACE. It is used for the detection of chromosomal abnormalities. This will help the company to bring a revolution in the Indian market and help expand its market.

  • In June 2021, GENinCode announced its partnership with Eversana as its launch and commercialization partner will help to access the US market for the GENinCode portfolio of polygenic cardiovascular disease products mainly focused on genetic risk.

  • In January 2019, Myriad Genetics and Illumina have developed a strategic partnership in the realm of oncology. The strategic connection between Myriad and Illumina includes a time-limited exclusive agreement for Illumina to deliver a kit-based version of the myChoice CDx test for overseas markets.


Report Overview:


The study covers the existing short-term and long-term market effects, helping decision-makers draft short-term and long-term plans for businesses by region. The report covers major regions in the US, Canada, UK, Germany, Spain, Japan, others. The report analyzes market drivers, restraints, opportunities, challenges, Porter's Five Forces, Value Chain, and impact of COVID-19 on the market.


Scope of the Report & Segmentation


Global Human Genetics Market, by Application



  • Wellness & E-Commerce

  • Preventive Medicine

  • Diagnostic & Treatment

    • Oncology

    • Cardiology

    • Assisted Reproduction

    • Neurology

      • Neuropediatric

      • Others





  • Gynecology

  • Others


Global Human Genetics Market, by Test



  • NIPT

  • Carrier Testing

  • Pharmacogenomic Testing

  • Thrombophilia Testing

  • Septin 9 Biomarker Testing

  • NGS

    • Oncology

    • Cardiology

    • Others

    • Others




Global Human Genetics Market, by Region



  • US

  • Canada

  • UK

  • Germany

  • Spain

  • Japan

  • Others



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: USD 1,12,536.54 Million
  CAGR   17.76%
  Base Year   2020
  Forecast Period   2021-2027
  Historical Data   2018 & 2019
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Application, Test, and Region
  Geographies Covered   US, Canada, UK, Germany, Spain, Japan, Others
  Key Vendors   Myriad Genetics (US) Synlab Group (Germany) Eurofins Megalab S.A (Spain) Biomarker Technology (US) Echevarne Laboratory (Spain) Elabscience Biotechnology Inc (US) NIMGenetics (Spain) Sistemas Genómicos (Spain) FullGenomics (Spain) GENinCode (UK) Atrys Health (Spain) Genyca (Spain) Igenomix (India) Genologica (Spain) Bode Technology Group Inc (US)
  Key Market Opportunities   • Growing use of genetic data across healthcare and technological advancement in genetic testing
  Key Market Drivers   • Growing adoption of genetic testing • Increasing incidences of genetic diseases and cancer


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

An expanding number of patients suffering from genetic diseases, capital spending, increased public awareness, and a growing demand for personalised and accurate drug are anticipated to be the primary drivers of the Human Genetics Market during the forecast timeframe, according to industry analysts.

The Asia Pacific region is predicted to account for the largest proportion of the global human genetics market.